MedTrace Logo

Idiopathic Bronchiectasis and Pulmonary Hypertension

NCT03883048 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1606

Last updated 2023-10-03

No results posted yet for this study

Summary

Patients with idiopathic bronchiectasis who received right heart catheterization (RHC) were included to evaluate the consistency between pulmonary arterial pressure (PAP) and other noninvasive indicators (pulmonary arterial systolic pressure \[PASP\] calculated by echocardiography, main pulmonary artery \[MPA\] diameter and MPA/ascending aorta ratio on chest high-resolution computed tomography \[HRCT\]). Then the optimal noninvasive indicator for identify PH was determined and its critical point was obtained according to the Youden Index. Based on this, we investigate the proportion, risk factors and prognosis of PH in idiopathic bronchiectasis patients in another large-scale population.

Conditions

Interventions

OTHER

Observation of bronchiectasis with pulmonary hypertension

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Jin-fu Mr Xu, Doctor · Shanghai Pulmonary Hospital, Shanghai, China

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03883048 on ClinicalTrials.gov